Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

Eli Lilly's drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months.

Eli Lilly announced that the highest doses of tirzepatide (Zepbound) -- 12.5 mg and 15 mg -- will soon be available in single ...

Part of the appeal of amylin analogs is the potential to drive weight loss without causing the same level of tolerability problems as GLP-1 receptor agonists. Lilly reported relatively low rates of ...

In today's Pharmalittle roundup, we're reading about a Lilly deal, a gene therapy shock for Duchenne families, and more.

Eli Lilly lands an $870 million pact with Camurus to build long-acting obesity treatments, tapping FluidCrystalslow-release ...

Eli Lilly’s (NYSE:LLY) experimental obesity ... Mid-stage trials designed to test eloralintide as a single agent and in combination with LLY's blockbuster weight loss drug Zepbound are also ...

Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

Eli Lilly has struck a deal to buy Crispr gene-editing start-up Verve Therapeutics for up to $1.3bn, the latest acquisition ...

June 13 (Reuters) - Eli Lilly's (LLY.N), opens new tab experimental obesity drug, eloralintide ... digestion and suppresses hunger. Mid-stage trials are ongoing, both as a standalone treatment ...